Curis (CUS0) Stock Overview
A biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CUS0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Curis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.88 |
| 52 Week High | US$4.22 |
| 52 Week Low | US$0.88 |
| Beta | 4.01 |
| 1 Month Change | -18.98% |
| 3 Month Change | -37.05% |
| 1 Year Change | -71.03% |
| 3 Year Change | -91.50% |
| 5 Year Change | -99.28% |
| Change since IPO | -99.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| CUS0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -10.3% | 1.7% | 0.1% |
| 1Y | -71.0% | -30.9% | 13.5% |
Return vs Industry: CUS0 underperformed the German Biotechs industry which returned -30.9% over the past year.
Return vs Market: CUS0 underperformed the German Market which returned 13.5% over the past year.
Price Volatility
| CUS0 volatility | |
|---|---|
| CUS0 Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: CUS0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CUS0's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 34 | Jim Dentzer | www.curis.com |
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3.
Curis, Inc. Fundamentals Summary
| CUS0 fundamental statistics | |
|---|---|
| Market cap | €11.64m |
| Earnings (TTM) | -€31.05m |
| Revenue (TTM) | €9.89m |
Is CUS0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CUS0 income statement (TTM) | |
|---|---|
| Revenue | US$11.65m |
| Cost of Revenue | US$31.71m |
| Gross Profit | -US$20.05m |
| Other Expenses | US$16.50m |
| Earnings | -US$36.56m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.83 |
| Gross Margin | -172.15% |
| Net Profit Margin | -313.79% |
| Debt/Equity Ratio | -194.9% |
How did CUS0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/27 20:44 |
| End of Day Share Price | 2025/12/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Curis, Inc. is covered by 20 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| James Birchenough | BMO Capital Markets Equity Research |
| Justin Walsh | B. Riley Securities, Inc. |